Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Encapsulating Childhood Leukemia Drugs in Nanoparticles Diminishes Toxic Side Effects

By LabMedica International staff writers
Posted on 19 Dec 2012
Cancer researchers have demonstrated that highly toxic chemotherapy agents used to treat childhood leukemia could be safely administered in much lower effective doses when the drugs were encapsulated in polymer nanoparticles.

Investigators at the University of Delaware (Wilmington, USA) prepared polymeric nanoparticles with an average diameter of 110 nanometers from an amphiphilic block copolymer of poly(ethylene glycol) (PEG) and poly(epsilon-caprolactone) (PCL) bearing pendant cyclic ketals (ECT2). More...
These nanoparticles were not toxic when added to cultured cells in vitro or administered to mice in vivo. Studies using nanoparticles labeled with fluorescent dyes revealed leukemic cell surface binding and internalization. In vivo biodistribution studies showed accumulation of nanoparticles in the liver and spleen with subsequent clearance of the particles with time.

The investigators prepared nanoparticles with encapsulated dexamethasone (Dex), one of the most common chemotherapeutic drugs used in the treatment of childhood leukemia. While Dex and similar drugs produce five-year survival rates for juvenile acute lymphoblastic leukemia (ALL) patients approaching 90%, the deleterious side effects of these drugs, including secondary cancers and fertility, cognitive, hearing, and developmental problems, raise significant quality of life issues.

Results of studies with encapsulated Dex published in the November 29, 2012, online edition of the journal Molecular Pharmaceutics revealed that encapsulation of Dex into the nanoparticles (Dex-NP) did not compromise the bioactivity of the drug. Dex-NPs induced glucocorticoid phosphorylation and showed cytotoxicity similar to free Dex in leukemic cells. In a preclinical model of leukemia, Dex-NPs significantly improved the quality of life and survival of mice as compared to the free drug.

"There are currently seven or eight drugs that are used for chemotherapy to treat leukemia in children," said senior author Dr. A. K. Rajasekaran, professor of biological sciences at the University of Delaware. "They are all toxic and do their job by killing rapidly dividing cells. However, these drugs do not differentiate cancer cells from other, healthy cells. The good news is that these drugs are 80%–90% effective in curing leukemia. The bad news is that many chemotherapeutic treatments cause severe side effects, especially in children. Encapsulating the drug uses one third of the typical dose, with good treatment results and no discernible side effects. In addition, the mice that received the drugs delivered via nanoparticles survived longer than those that received the drug administered in the traditional way."

Related Links:
University of Delaware



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.